RT Journal Article
SR Electronic
T1 A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.10.22270086
DO 10.1101/2022.02.10.22270086
A1 Mitin, Natalia
A1 Nyrop, Kirsten A.
A1 Strum, Susan L.
A1 Knecht, Anne
A1 Carey, Lisa A
A1 Reeder-Hayes, Katherine E.
A1 Dees, E. Claire
A1 Jolly, Trevor A.
A1 Kimmick, Gretchen G.
A1 Karuturi, Meghan S.
A1 Reinbolt, Raquel E.
A1 Speca, JoEllen C.
A1 O’Hare, Erin A.
A1 Muss, Hyman B.
YR 2022
UL http://medrxiv.org/content/early/2022/02/14/2022.02.10.22270086.abstract
AB Importance Identifying patients at higher risk of chemotherapy-induced peripheral neuropathy (CIPN) is a major unmet need given its high incidence, persistence, and detrimental effect on quality of life.Objective To determine if expression of p16, a biomarker of aging and cellular senescence, predicts CIPN.Design Prospective observational cohort study including one hundred fifty-two participants enrolled between January 2014 and August 2018 and followed during the course of adjuvant chemotherapy. Expression of p16 was measured prior to and at the end of chemotherapy. Side effects, including peripheral neuropathy, were assessed prior to each chemotherapy cycle.Setting A multi-center study including four major academic hospitals and five community oncology clinics.Participants Women with newly diagnosed with stage I to III breast cancer to receive chemotherapy including a taxane.Main Outcomes and Measure Development of grade 2+ (moderate or worse) CIPN during the course of chemotherapy. CIPN symptoms were graded by participants’ oncology clinician using the NCI-CTCAE v5 system. Expression of p16 mRNA was measured by qPCR in T-lymphocytes isolated from fresh peripheral blood.Results A multivariate model including taxane regimen type and p16Age Gap, a measure of discordance between chronological age and p16 expression, identified risk factors for CIPN. Participants with higher chronological age but lower p16 expression prior to chemotherapy (molecularly young) were at the highest risk. Incidence of CIPN positively correlated with chemotherapy-induced increase in p16 expression, with the largest increase seen in participants with the lowest p16 expression prior to treatment.Conclusions and Relevance This is the first report using a biomarker of senescence in a model to identify patients at risk for taxane-induced CIPN. Studies to confirm and validate our findings are ongoing. When validated, a p16Age Gap-based model can be used to guide chemotherapy selection in patients with early breast cancer and identify patients at high risk who may be candidates for preventive trials.Question Is cellular senescence an independent risk factor for chemotherapy-induced peripheral neuropathy?Findings In a prospective observational cohort study of women with early-stage breast cancer undergoing treatment with taxane chemotherapy, a regression model containing a measure of cellular senescence and taxane type was a statistically significant predictor of grade 2+ CIPN incidence.Meaning Cellular senescence is an independent risk factor for CIPN that, if validated, could guide treatment selection and identify high-risk patients for preventive strategies.Competing Interest StatementNM is a co-founder of Sapere Bio. NM, SLS, and AK hold equity in the company and NM and AK are inventors on intellectual property applications.Funding StatementThis work was supported by grants from Breast Cancer Research Foundation (NY, NY), Kay Yow Cancer Fund (Raleigh, NC), UNC Lineberger Comprehensive Cancer Center/University Cancer Research Fund (Chapel Hill, NC) and NIH/NCI R01 CA203023. The funding sources had no involvement in the study design or in the collection, analysis and interpretation of data. The funding sources also had no involvement in the writing of this report or in the decision to submit the report for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Studies were led by the University of North Carolina with REX Healthcare, Ohio State University, MD Andersen, and Duke University participating, and approved by the IRB of participating sites. The study was performed in agreement with the guidelines of the International Conference on Harmonization, the ethical principles in the Declaration of Helsinki, and all applicable regulations.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript